Skip to content

The effect of Amiodarone in heart surgery patients prone to atrial fibrillation

Comparison of prophylactic and therapeutic effect of amiodarone in heart surgery patients at risk of atrial fibrillation

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210424051058N1
Enrollment
200
Registered
2021-05-27
Start date
2021-06-21
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation. Atrial fibrillation and flutter

Interventions

Intervention 1: Intervention group: In the intervention group, patients will receive 350 mg of amiodarone as an intravenous infusion 24 hours before surgery. Within 30 minutes to 24 hours after admiss
Premature atrial fibrillation
Branch blocks
Asystole
VF ..... is recorded and also cardiac arrhythmias and interventions performed according to the opinion of the surgeon or anesthesiologist. Intervention 2: Control group: In the control group, amiodaro

Sponsors

Hamedan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Candidate patients for elective cardiac surgery ASA class 2 & 3 Consent to participate in the study Having a sinus rhythm before surgery No history of amiodarone allergy

Exclusion criteria

Exclusion criteria: Recipients of antihypertensive drugs except beta blockers and ACE inhibitors Patients with thyroid, renal, pulmonary, hepatic disorders Asthmatics Rate of less than 50 Heart failure Atrioventricular block

Design outcomes

Primary

MeasureTime frame
Atrial fibrillation: It means uncoordinated atrial activity and consequent mechanical atrial insufficiency. Timepoint: The outcome of the intervention will be reviewed and compared before the intervention and one week after the intervention. Method of measurement: ECG.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehran Jabbari

Hamedan University of Medical Sciences

mehran_jabbari@yahoo.com+98 918 811 2759

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026